Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

LA JOLLA, Calif., Nov. 14 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced financial results for the third quarter ended September 30, 2007. For the three-month period, the Company posted revenue of $2.5 million and a net loss of $6.8 million. Cash and cash equivalents totaled $39.7 million at September 30, 2007.

"Last quarter we continued to advance our three priority product candidates and most notably, after the quarter ended, we announced positive results from our Phase IIb clinical trial evaluating our lead compound, tezampanel, in acute migraine," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "We now have two migraine studies in which tezampanel demonstrated statistically significant improvement on the primary end point of pain response at two hours post-dose compared to placebo. These Phase IIb results further establish the efficacy and safety of tezampanel and we are pleased to be advancing tezampanel into later-stage clinical development."

Highlights:

-- In October 2007, announced that tezampanel met the primary endpoint at

the 40 mg dose in a 306-patient, Phase IIb clinical trial for the

treatment of a single, acute migraine attack. Two other doses, 70 mg

and 100 mg, were evaluated and also demonstrated effects across a

number of pain measurements although neither dose reached statistical

significance on the primary endpoint. In this trial, tezampanel was

well-tolerated and there were no serious or medically important

adverse events reported.

-- Initiated a Phase I multiple-dose clinical trial of tezampanel to

evaluate the safety, tolerability
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... Graphite Metallizing ... process equipment, announces the appointment of Dennis Rawle as European Director of Sales. ... Most recently, he was General Manager and Technical Sales Manager for pump products ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... (POC) diagnostic tests – today announced that Robert A. Gregg, PhD, has joined ... more than 30 years of relevant experience and remarkable achievements in the medical ...
(Date:8/4/2015)...  Natera, Inc. (Nasdaq: NTRA ), a leader ... cell-free DNA, today announced that it will release results ... the market close on August 12, 2015. Natera will ... PT (4:30 p.m. ET) to discuss its financial results, ... Conference Call  Date: , Wednesday, August 12, 2015  Time:  ...
(Date:8/4/2015)... , Aug. 4, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: ... in China , today announced that ... second quarter, ended June 30, 2015, after market close ... conference call on Thursday, August 13, 2015, at 8:00 ... China Standard Time) to review the Company,s financial results ...
Breaking Biology Technology:Dennis Rawle Joins Graphite Metallizing Corporation 2RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 2RPS Diagnostics Welcomes Robert Gregg as Senior Vice President of Clinical and Regulatory Affairs 3Natera to Release Second Quarter 2015 Results on August 12, 2015 2Sinovac to Host Conference Call to Report Second Quarter 2015 Unaudited Financial Results 2
... ... PX1500-4 high-speed digitizer, the most advanced PCIe-based wideband A/D board on the market. The ... channels up to an amazing 3 GHz when interleaving the ADC data. , ... Newport Beach, California (PRWEB) December 18, 2009 ...
... NEW YORK, Dec. 18 /PRNewswire-Asia-FirstCall/ -- American ... or "AOBO"), a pharmaceutical,company dedicated to improving health through ... prescription and over the counter ("OTC"),products, today announced that ... National (Medical) Insurance Catalog (the "2009 NIC"). Of these, ...
... , Toronto Stock Exchange Symbol: MS ... MS) today provided the following update on corporate developments: , ... , The Company has completed its substantive review of the ... candidate for the treatment of multiple sclerosis (MS). BioMS has ...
Cached Biology Technology:Signatec Releases PX1500-4, Its 4-Channel, 1.5 GHz Per Channel / 2-Channel, 3 GHz Per Channel PCI-Express Digitizer with Two Virtex-5 FPGAs 2Signatec Releases PX1500-4, Its 4-Channel, 1.5 GHz Per Channel / 2-Channel, 3 GHz Per Channel PCI-Express Digitizer with Two Virtex-5 FPGAs 3Signatec Releases PX1500-4, Its 4-Channel, 1.5 GHz Per Channel / 2-Channel, 3 GHz Per Channel PCI-Express Digitizer with Two Virtex-5 FPGAs 4American Oriental Bioengineering Announces the Inclusion of 158 Drugs in China's National Insurance Catalog 2American Oriental Bioengineering Announces the Inclusion of 158 Drugs in China's National Insurance Catalog 3BioMS Medical provides corporate update 2BioMS Medical provides corporate update 3
(Date:7/23/2015)... Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... today reported financial results for its second quarter ended June ... of 2015 was $4.5 million, a decrease of 33% compared ... income in the second quarter of 2015 was $0.3 million, ... or $0.04 per diluted share, in the same period a ...
(Date:7/20/2015)... -- Acuity Market Intelligence,s latest research "The Global Biometrics ... Privacy" forecasts that between 2014 and 2020 nearly ... to smart mobile devices by 2.2 billion mobile ... to generate more than $67.9 billion in total ...    "Biometrics is at the center ...
(Date:7/9/2015)...  Unchained Labs just can,t get enough biologics ... Nano. Avid Nano designs, develops and manufactures highly ... Also today, Unchained Labs UNcaged the pUNk, ... protein sizing system. The pUNk is a high-performance ... size distribution, aggregation population and molecular weight. Its ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... speakers and panelists from the U.S. Centers for Disease ... AIDS Institute, and the Semel Institute for Neuroscience and ... which genetics, race and health care disparities prevent or ... the UCLA AIDS Institute, will include a press conference ...
... legs in a camera trap photo snapped in an African ... Wildlife Conservation Society. The legs belong to an okapia rare ... Congo,s Virunga National Park, despite over a decade of civil ... time this species has been captured on film in this ...
... -- Earlier today, some 300 feet below the Earth,s ... travels from Switzerland into France and back again, scientists ... Organization for Nuclear Research (CERN) in Geneva fired the ... produce history-making science. A contingent of more than ...
Cached Biology News:Photo reveals rare okapi survived poaching onslaught 2UC Santa Barbara has key role in Large Hadron Collider project 2UC Santa Barbara has key role in Large Hadron Collider project 3UC Santa Barbara has key role in Large Hadron Collider project 4
... Although the mixed TAMRA isomers are predominantly ... are increasingly preferred for labeling peptides and ... HPLC purification that is often required in ... used than 6-TAMRA for labeling peptides and ...
anti-Lactate Dehydrogenase...
Mouse monoclonal [6E10] to LAP2 ( Abpromise for all tested applications). entrezGeneID: 7112 SwissProtID: P42166...
Alkali soluble casein is the recommended blot blocking reagent for use with the HisTag Monoclonal Antibody (Novagen) on Western blots....
Biology Products: